From USFDA
Zydus Pharmaceuticals Inc., a wholly owned subsidiary of Cadila Healthcare has received final approval from USFDA to market Minocycline Hydrochloride Extended Release Tablets in strengths of 45 mg, 80 mg, 90 mg, 105 mg and 135 mg. Zydus has also received the tentative approval for Minocycline Hydrochloride Extended Release Tablets, 55 mg, 65 mg and 115 mg.Minocycline Hydrochloride Extended Release Tablets are a tetracycline class drug, indicated to treat only inflammatory lesions of non nodular moderate to severe acne vulgaris in patients 12 year of age and older.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
